Drugs / CK-0045
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05712876 | Dec 2022 → Jan 2024 | — | Cytoki Pharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06611930 | Sep 2024 → Sep 2025 | obesity disorder, type 2 diabetes mellitus | Cytoki Pharma | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-05-08 | Cytoki Pharma | Results Cytoki Pharma Highlights Data Reinforcing Therapeutic Potential of Lipidated IL-22 for IBD in Digestive Diseases and Sciences Publication cytokipharma.com ↗
Cytoki Pharma ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of medicines that harness interleukin-22 (IL-22) biology to drive improved metabolic and other health outcomes, today announced the publication of preclinical data demonstrating the efficacy of its novel lipidated IL-22 analogue in a model of inflammatory bowel disease (IBD) in Digestive Diseases and Sciences. |
| 2024-07-23 | Cytoki Pharma | Results Cytoki Announces Positive Phase 1 Data for CK-0045 cytokipharma.com ↗ |
| 2023-10-16 | Cytoki Pharma | Results Cytoki Presents Preclinical Data at ObesityWeek 2023 cytokipharma.com ↗
today presented preclinical data demonstrating the potential of lipidated IL-22 to induce weight loss and positively impact a range of cardiometabolic risk factors at ObesityWeek 2023, held October 14-17 in Dallas. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-08 | Cytoki Pharma | Cytoki Pharma Highlights Data Reinforcing Therapeutic Potential of Lipidated IL-22 for IBD in Digestive Diseases and Sciences Publication cytokipharma.com ↗ |
| 2024-11-04 | Cytoki Pharma | Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes cytokipharma.com ↗ |
| 2024-07-23 | Cytoki Pharma | Cytoki Announces Positive Phase 1 Data for CK-0045 cytokipharma.com ↗ |
| 2023-10-16 | Cytoki Pharma | Cytoki Presents Preclinical Data at ObesityWeek 2023 cytokipharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CK-0045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06611930 ↗ |
| Route | Subcutaneous | “given subcutaneously” NCT05712876 ↗ |